Morning Seminar Vol 2 April 2005-June 2005
Basic knowledge of chemotherapy 1
MLD 21
Mutation in TERT, the gene for telomerase RT, in AA (Yamaguchi, N Engl J Med 2005) 22
8th Infant Leukemia Seminar (1) 23
Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment (Jordan, Eur J Cancer 2005) 26
Juvenile granulosa cell tumor 29
HDC with autologous stem cell rescue for children with highrisk and recurrent medulloblastoma and supratentorial PNET (Perez-Martinez, J Neurooncol 2005) 33
8th Infant Leukemia Seminar (2) 36
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic BMT for childhood ALL (Dai, BMT 2004) 38
Taxane chemotherapeutic drugs 41
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: A COG study (Demirer, JCO 2004) 46
Arrythmia 48
Cardiac function 52
Serial evaluation of academic and behavioral outcome after treatment cranial radiation in childhood (Mabott, JCO 2005) 54
Hypercalcemia and malignancy 56
Dose intensity and the toxicity and efficacy of allogeneic hematopoietic transplantation (Appelbaum, Leukemia 2005) 63
Thrombotic microangiophathy with diarrhea 67
GVT effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning (Baron, JCO 2005) 75
Congenital pure red cell aplasia 83
Use of Oseltamivir to control influenza complications after BMT (Machado, BMT 2004) 85
Vascular endothelial function in survivors of childhood cancer 90
Kawasaki Disease 98
Final adult height of patients who received hematopoietic cell transplantation in childhood (Sanders, Blood 2005) 100
Analysis of 96 patients with advanced ovarian carcinoma treated with HDC and ASCT (Donato, BMT 2004)
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer (Donato, Gynecol Oncol 2001)
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia (Cooper, Clin Cancer Res 2004) 104
Symposium for Fludara’s 5th anniversary
Non-myeloablative SCT 108
DNA topoisomerase II in therapy-related APL (N Engl J Med 2005) 110
The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 1 115
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk NB (Kushner, JCO 2004) 118
The effect of first-line imatinib interim therapy on the outcome of allogeneic SCT in adults with newly diagnosed Philadelphia chromosome-positive ALL (Lee, Blood 2005) 120
The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 2 122
Accidental busulfan overdose during conditioning for SCT (Junke, BMT 2005) 125
J Jpn Pediatr 19(2), 2005 129
Somnolence syndrome 136
Allogeneic hematopoietic cell transplantation for infants with ALL (Sanders, Blood 2005) 137
JACLS（MLL-98） 141
RIST #1 143
Genetic subtypes of FHL: correlations with clinical features and CTL/NK cell functions (Blood 2005) 152
RIST #2 155
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 159
Rituximab plus short-duration chemotherapy as first-line treatment for follicular NHL: a phase II trial of the Minnie Pearl Cancer Research Network (Hainswroth, JCO 2005) 163
HDF 167
Expression of IL-10 splicing variants is a positive prognostic feature in relapsed ALL (Wu, JCO 2005) 170
Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management (Tabori, Cancer 2005) 173
Postoperative chemotherapy in advanced ovarian granulosa cell tumors (Al-Badawi, Int J Gynecol Cancer 2002) 176
Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic SCT recipients (Abdelkefi, BMT 2005) 178
Unrelated donor SCT compared with chemotherapy for children with ALL in a second remission: a matched-pair analysis (Borgmann, Blood 2003) 182
Tacrolimus-related encephalopathy following allogeneic SCT in children (Kanekiyo, Int J Hematol 2005) 186
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT (Wong, Br J Haematol 2003) 188
Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose (Minneci, Ann Intern Med 2004) 192
Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with ALL (Stephan, JCO 2005) 196
A prospective randomized study of clinical and economic consequences of using G-CSF following autologous PBPC transplantation in children (Gonzalez-Vincent, BMT 2004) 200
The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 206
Transplantation of 2 partially HLA-matched umbilical cord blood units with malignant disease (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 208
Umbilical CBT in Europe: An Eurocord survey (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 216
Sensitivity to L-Asp is not associated with expression levels of AS in t(12;21)+ pediatric ALL (Wendy, Blood 2003) 222
AS expression is linked with L-Asp resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric ALL (Wendy, Blood 2005) 224
Duration of immunosuppressive treatment for cGVHD (Stewart, Blood 2004) 226
CBTs from unrelated donors in patients with Hurler’s syndrome (Staba, N Engl J Med 2004) 230
Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease (Escolar, N Engl J Med 2005) 232
Effect of SCT on seven cases of leucodystrophy 237
J Jpn Pediatr 109 (5), 2005 242
High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international NB staging system stage II and III NB with MYCN amplification (Laprie, Cancer 2004) 245
10th Pediatric MDS Study group （2005.6.5 Tokyo） 249
Ovarian granulosa cell tumors in childhood (Marras-Salmio, Pediatr Hematol Oncol 2002) 257
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from BMT survivor study (Bhatia, Blood 2005) 261
Results of treatment for NB 265
Reports on allogeneic SCT for pediatric solid tumor 267
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated NB treated in an upfront Phase II investigation window: a Pediatric Oncology Group study (JCO 2004) 268
12th Pediatric AA Study group (2005.6.4 Tokyo) 272
HLA typing of JMDP 277
Aplastic anemia (Brodsky, Lancet 2005) 278
Life-threatening neurological complications after BMT in children (Uckan, BMT 2005) 284
PFAPA (9th Osaka Pediatric Immunology Study Group 2005.6.9) 286
Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial (Benoehr, J Am Soc Nephrol 2005) 294
Use of rituximab to treat refractory Diamond-Blackfan anemia (Morimoto, Eur J Hematol 2005) 297
Steroids prevent engraftment syndrome after autologous hematopoietic SCT without increasing the risk of infection (Mossad, BMT 2005) 300
Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome (Gonzalez-Vincent, BMT 2004) 301
Autologous PBSCT with induction of autologous GVHD in AML (Park, BMT 2003) 303
CIAS1 mutation (CINCA, FCAS, Muckle-Wells syndrome)
304
Asthma as a consequence of BMT (Rietz, Chest 2002) 310
Immune reconstitution after childhood ALL is most severely affected in the high risk group (Torben, Pediatr Blood Cancer 2005) 312
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: a children’s oncology group study (Walterhouse, JCO 2004) 316
Micafungin versus fluconazole for prophylaxis against fungal infections during neutropenia in patients undergoing hematopoietic SCT (van Burik, Clin Infect Disease 2004) 320
After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B (Shetelig, Transfusion 2005) 322
Exacerbating factor of allergy after pediatric liver transplantation
325
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 332
Neuropsychological performance and QOL of 10 year survivors of childhood medulloblastoma (Maddrey, J Neurooncol 2005) 335
The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 337
Long term follow-up after splenectomy peformed for ITP (Schwartz, Am J Hematol 2003) 340
Alveolar soft part sarcoma 343
MLD 21
Mutation in TERT, the gene for telomerase RT, in AA (Yamaguchi, N Engl J Med 2005) 22
8th Infant Leukemia Seminar (1) 23
Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment (Jordan, Eur J Cancer 2005) 26
Juvenile granulosa cell tumor 29
HDC with autologous stem cell rescue for children with highrisk and recurrent medulloblastoma and supratentorial PNET (Perez-Martinez, J Neurooncol 2005) 33
8th Infant Leukemia Seminar (2) 36
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic BMT for childhood ALL (Dai, BMT 2004) 38
Taxane chemotherapeutic drugs 41
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: A COG study (Demirer, JCO 2004) 46
Arrythmia 48
Cardiac function 52
Serial evaluation of academic and behavioral outcome after treatment cranial radiation in childhood (Mabott, JCO 2005) 54
Hypercalcemia and malignancy 56
Dose intensity and the toxicity and efficacy of allogeneic hematopoietic transplantation (Appelbaum, Leukemia 2005) 63
Thrombotic microangiophathy with diarrhea 67
GVT effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning (Baron, JCO 2005) 75
Congenital pure red cell aplasia 83
Use of Oseltamivir to control influenza complications after BMT (Machado, BMT 2004) 85
Vascular endothelial function in survivors of childhood cancer 90
Kawasaki Disease 98
Final adult height of patients who received hematopoietic cell transplantation in childhood (Sanders, Blood 2005) 100
Analysis of 96 patients with advanced ovarian carcinoma treated with HDC and ASCT (Donato, BMT 2004)
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer (Donato, Gynecol Oncol 2001)
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia (Cooper, Clin Cancer Res 2004) 104
Symposium for Fludara’s 5th anniversary
Non-myeloablative SCT 108
DNA topoisomerase II in therapy-related APL (N Engl J Med 2005) 110
The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 1 115
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk NB (Kushner, JCO 2004) 118
The effect of first-line imatinib interim therapy on the outcome of allogeneic SCT in adults with newly diagnosed Philadelphia chromosome-positive ALL (Lee, Blood 2005) 120
The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 2 122
Accidental busulfan overdose during conditioning for SCT (Junke, BMT 2005) 125
J Jpn Pediatr 19(2), 2005 129
Somnolence syndrome 136
Allogeneic hematopoietic cell transplantation for infants with ALL (Sanders, Blood 2005) 137
JACLS（MLL-98） 141
RIST #1 143
Genetic subtypes of FHL: correlations with clinical features and CTL/NK cell functions (Blood 2005) 152
RIST #2 155
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 159
Rituximab plus short-duration chemotherapy as first-line treatment for follicular NHL: a phase II trial of the Minnie Pearl Cancer Research Network (Hainswroth, JCO 2005) 163
HDF 167
Expression of IL-10 splicing variants is a positive prognostic feature in relapsed ALL (Wu, JCO 2005) 170
Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management (Tabori, Cancer 2005) 173
Postoperative chemotherapy in advanced ovarian granulosa cell tumors (Al-Badawi, Int J Gynecol Cancer 2002) 176
Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic SCT recipients (Abdelkefi, BMT 2005) 178
Unrelated donor SCT compared with chemotherapy for children with ALL in a second remission: a matched-pair analysis (Borgmann, Blood 2003) 182
Tacrolimus-related encephalopathy following allogeneic SCT in children (Kanekiyo, Int J Hematol 2005) 186
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT (Wong, Br J Haematol 2003) 188
Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose (Minneci, Ann Intern Med 2004) 192
Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with ALL (Stephan, JCO 2005) 196
A prospective randomized study of clinical and economic consequences of using G-CSF following autologous PBPC transplantation in children (Gonzalez-Vincent, BMT 2004) 200
The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 206
Transplantation of 2 partially HLA-matched umbilical cord blood units with malignant disease (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 208
Umbilical CBT in Europe: An Eurocord survey (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 216
Sensitivity to L-Asp is not associated with expression levels of AS in t(12;21)+ pediatric ALL (Wendy, Blood 2003) 222
AS expression is linked with L-Asp resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric ALL (Wendy, Blood 2005) 224
Duration of immunosuppressive treatment for cGVHD (Stewart, Blood 2004) 226
CBTs from unrelated donors in patients with Hurler’s syndrome (Staba, N Engl J Med 2004) 230
Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease (Escolar, N Engl J Med 2005) 232
Effect of SCT on seven cases of leucodystrophy 237
J Jpn Pediatr 109 (5), 2005 242
High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international NB staging system stage II and III NB with MYCN amplification (Laprie, Cancer 2004) 245
10th Pediatric MDS Study group （2005.6.5 Tokyo） 249
Ovarian granulosa cell tumors in childhood (Marras-Salmio, Pediatr Hematol Oncol 2002) 257
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from BMT survivor study (Bhatia, Blood 2005) 261
Results of treatment for NB 265
Reports on allogeneic SCT for pediatric solid tumor 267
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated NB treated in an upfront Phase II investigation window: a Pediatric Oncology Group study (JCO 2004) 268
12th Pediatric AA Study group (2005.6.4 Tokyo) 272
HLA typing of JMDP 277
Aplastic anemia (Brodsky, Lancet 2005) 278
Life-threatening neurological complications after BMT in children (Uckan, BMT 2005) 284
PFAPA (9th Osaka Pediatric Immunology Study Group 2005.6.9) 286
Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial (Benoehr, J Am Soc Nephrol 2005) 294
Use of rituximab to treat refractory Diamond-Blackfan anemia (Morimoto, Eur J Hematol 2005) 297
Steroids prevent engraftment syndrome after autologous hematopoietic SCT without increasing the risk of infection (Mossad, BMT 2005) 300
Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome (Gonzalez-Vincent, BMT 2004) 301
Autologous PBSCT with induction of autologous GVHD in AML (Park, BMT 2003) 303
CIAS1 mutation (CINCA, FCAS, Muckle-Wells syndrome)
304
Asthma as a consequence of BMT (Rietz, Chest 2002) 310
Immune reconstitution after childhood ALL is most severely affected in the high risk group (Torben, Pediatr Blood Cancer 2005) 312
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: a children’s oncology group study (Walterhouse, JCO 2004) 316
Micafungin versus fluconazole for prophylaxis against fungal infections during neutropenia in patients undergoing hematopoietic SCT (van Burik, Clin Infect Disease 2004) 320
After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B (Shetelig, Transfusion 2005) 322
Exacerbating factor of allergy after pediatric liver transplantation
325
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 332
Neuropsychological performance and QOL of 10 year survivors of childhood medulloblastoma (Maddrey, J Neurooncol 2005) 335
The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 337
Long term follow-up after splenectomy peformed for ITP (Schwartz, Am J Hematol 2003) 340
Alveolar soft part sarcoma 343
posted by hohtaped @ 5:42 AM
<< Home